Insight Molecular Diagnostics Inc. Impairment of Long-Lived Assets Held-for-use
Insight Molecular Diagnostics Inc. (IMDX) reported Impairment of Long-Lived Assets Held-for-use of $169.00 thousand for the 9-month period ending 2025-09-30, per its 10-Q filed 2025-11-10.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:ImpairmentOfLongLivedAssetsHeldForUse · last filed 2026-03-26
- Insight Molecular Diagnostics Inc. impairment of long-lived assets held-for-use for the quarter ending 2025-09-30 was $0.00.
- Insight Molecular Diagnostics Inc. impairment of long-lived assets held-for-use for the quarter ending 2024-12-31 was $0.00.
- Insight Molecular Diagnostics Inc. impairment of long-lived assets held-for-use for the quarter ending 2024-09-30 was $0.00.
- Insight Molecular Diagnostics Inc. impairment of long-lived assets held-for-use for the quarter ending 2024-06-30 was -$168.83M.
- Insight Molecular Diagnostics Inc. impairment of long-lived assets held-for-use for fiscal 2024 was $169.00K, a 87.00% decline from fiscal 2023.
- Insight Molecular Diagnostics Inc. impairment of long-lived assets held-for-use for fiscal 2023 was $1.30M.
| Period end | Impairment of Long-Lived Assets Held-for-use 3 month | Impairment of Long-Lived Assets Held-for-use 3 month as first filed | Impairment of Long-Lived Assets Held-for-use 6 month | Impairment of Long-Lived Assets Held-for-use 9 month | Impairment of Long-Lived Assets Held-for-use 9 month as first filed | Impairment of Long-Lived Assets Held-for-use 12 month |
|---|---|---|---|---|---|---|
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $169.00K 10-Q · filed 2025-11-10 | ||||
| 2025-06-30 | $169.00K 10-Q · filed 2025-08-11 | |||||
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-26 | $0.00 derived: sum of 2 quarters · filed 2026-03-26 | -$168.83M derived: sum of 3 quarters · filed 2026-03-26 | $169.00K 10-K · filed 2026-03-26 | ||
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | -$168.83M derived: sum of 2 quarters · filed 2024-11-12 | $169.00K 10-Q · filed 2024-11-12 | $169.00K derived: sum of 4 quarters · filed 2025-05-12 | ||
| 2024-06-30 | -$168.83M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $169.00K 10-Q · filed 2024-08-08 | $169.00K derived: sum of 3 quarters · filed 2025-05-12 | $169.00K derived: sum of 4 quarters · filed 2025-05-12 | ||
| 2024-03-31 | $169.00M 10-Q · filed 2025-05-12 | $169.00K 10-Q · filed 2024-05-15 | $169.00M derived: sum of 2 quarters · filed 2025-05-12 | $169.00M derived: sum of 3 quarters · filed 2025-05-12 | ||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-24 | $0.00 derived: sum of 2 quarters · filed 2025-03-24 | $1.30M 10-K · filed 2025-03-24 | |||
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | $1.30M 10-Q · filed 2024-11-12 | $5.00M 10-Q · filed 2023-11-09 | |||
| 2023-06-30 | $1.30M 10-Q · filed 2024-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IMMUCELL CORP /DE/ (ICCC) | United States | $0.091B | 116.10 |
| BIOMERICA INC (BMRA) | United States | $0.011B | |
| Q/C TECHNOLOGIES, INC. (QCLS) | United States | $0.008B | -1.93 |
| Cardio Diagnostics Holdings, Inc. (CDIO) | United States | $0.006B | |
| VOLITIONRX LTD (VNRX) | $0.003B | -0.64 | |
| MYRIAD GENETICS INC (MYGN) | United States | $0.397B | -4.84 |
| Alpha Teknova, Inc. (TKNO) | United States | $0.500B | -18.12 |
| QuidelOrtho Corp (QDEL) | United States | $0.733B | -0.90 |
| ACHIEVE LIFE SCIENCES, INC. (ACHV) | United States | $0.806B | -5.88 |
| Intellia Therapeutics, Inc. (NTLA) | United States | $1.705B | -5.92 |